Goodwin: CRISPR Therapeutics Commences $280M Registered Direct Offering
February 15, 2024
February 15, 2024
BOSTON, Massachusetts, Feb. 15 -- Goodwin, a law firm, issued the following news release:
The Life Sciences team advised CRISPR Therapeutics (Nasdaq: CRSP) on its investment agreement for the sale of approximately $280 million of its common shares to a select group of institutional investors in a registered direct offering, at a price per share of $71.50, representing a premium of greater than 10% to CRISPR Therapeutics' 30-day volume-weighted average price. The financing is ex . . .
The Life Sciences team advised CRISPR Therapeutics (Nasdaq: CRSP) on its investment agreement for the sale of approximately $280 million of its common shares to a select group of institutional investors in a registered direct offering, at a price per share of $71.50, representing a premium of greater than 10% to CRISPR Therapeutics' 30-day volume-weighted average price. The financing is ex . . .